Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 11,597 |
|
|||||
| News | - | ||||||
| Day High | 1.9798 | Low High |
|||||
| Day Low | 1.878 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Exagen Inc | XGN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.075 | 4.03% | 1.935 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.8899 | 1.878 | 1.9798 | 1.935 | 1.86 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 115 | 11,597 | US$ 1.94 | US$ 22,472 | - | 1.3003 - 3.4712 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:03:30 | 50 | US$ 2.02 | USD |
Exagen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 32.9M | 17.05M | - | 52.55M | -23.69M | -1.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Exagen News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical XGN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.84 | 2.00 | 1.8001 | 1.91 | 74,897 | 0.095 | 5.16% |
| 1 Month | 1.41 | 2.00 | 1.3188 | 1.76 | 70,385 | 0.525 | 37.23% |
| 3 Months | 1.93 | 2.05 | 1.3003 | 1.68 | 50,108 | 0.005 | 0.26% |
| 6 Months | 1.64 | 2.40 | 1.3003 | 1.82 | 52,487 | 0.295 | 17.99% |
| 1 Year | 3.05 | 3.4712 | 1.3003 | 1.92 | 34,425 | -1.12 | -36.56% |
| 3 Years | 13.97 | 17.58 | 1.3003 | 6.21 | 43,655 | -12.04 | -86.15% |
| 5 Years | 16.80 | 29.858 | 1.3003 | 10.59 | 46,231 | -14.87 | -88.48% |
Exagen Description
| Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
